Risperidone-induced changes in DNA methylation from peripheral blood in first-episode schizophrenia parallel neuroimaging and cognitive phenotype

Maolin Hu\textsuperscript{11} MD, Yan Xia\textsuperscript{2,3} MA, Xiaofen Zong\textsuperscript{1,4} MD, John A. Sweeney\textsuperscript{5} PhD, Jeffrey R Bishop\textsuperscript{6} PharmD, Yanhui Liao\textsuperscript{7}, Gina Giase\textsuperscript{8} MA, Bingshan Li\textsuperscript{9} PhD, Leah H. Rubin\textsuperscript{10} PhD, Yunpeng Wang\textsuperscript{11} PhD, Zongchang Li\textsuperscript{1,2} MA, Ying He\textsuperscript{1} MD, Xiaogang Chen \textsuperscript{1,13,14,15} MD, PhD, Chunyu Liu\textsuperscript{2,3} PhD, Chao Chen\textsuperscript{2,12} PhD, Jinsong Tang\textsuperscript{7,12,13,14,15} MD, PhD

1. Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
2. Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China
3. Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY
4. Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
5. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio
6. Department of Experimental and Clinical Pharmacology and Department of Psychiatry, University of Minnesota, Minneapolis, MN
7. Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China
8. Department of Psychiatry, University of Illinois at Chicago, Chicago, IL
9. Genetics Institute, Vanderbilt University School of Medicine, Nashville, TN
10. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
11. Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
12. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital,
Central South University, Changsha, China
13. Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
14. National Clinical Research Center on Mental Disorders, Changsha, Hunan 410011, China
15. National Technology Institute on Mental Disorders, Changsha, Hunan 410011, China
16. Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China

† These authors contributed equally to this work

* Corresponding Authors: Dr. Jinsong Tang, Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China; tangjinsong@zju.edu.cn; Tel: +86-18258457297
Chunyu Liu, liucy@uic.edu;
Chao Chen, chenchao@sklmg.edu.cn;
Xiaogang Chen, chenxiaogang@csu.edu.cn;

Funding and Disclosure
This work was supported by grants from the National Natural Science Foundation of China (81871057 and 81371480 to J.T; 81271484 and 81471361 to X.C.; 31970572, 81401114 and 31571312 to C.C.) the National Key Plan for Scientific Research and Development of China (2016YFC1306000) (to C. C.) and NIH grant 1 U01 MH103340-01, 1R01ES024988 (to C. L.), MH083888 (to J.R.B.). Wuhan Science and Technology Bureau grant (2017060201010169 to M. H.). Central South University Graduate Project grant (502221702 to Y.X.).
The authors have nothing to disclose.
ABSTRACT

Today, second generation anti-psychotics such as clozapine and risperidone are the favored treatment for schizophrenia. Yet, the absence of relevant biomarkers that can decode their neurobiological effect shackles our ability to accurately predict and track response to treatment. While researchers have investigated DNA methylation as a biomarker for schizophrenia risk, none have performed a systematic analysis of the effect of antipsychotics upon DNA methylation. We hypothesize that disease-related methylation changes occur before treatment, and that acute antipsychotic treatment may affect DNA methylation. We designed a longitudinal DNA methylation study to estimate risperidone’s effect on DNA methylation and how changes in DNA methylation might influence risperidone’s therapeutic effect on behavioral and neuroimaging phenotypes. Thirty-eight patients with first-episode drug-naïve schizophrenia (FES) and 38 demographically-matched individuals (healthy controls) participated. We identified brain related pathways enriched in 8,204 FES-associated methylation sites. Risperidone administration altered methylation in 6,143 CpG DNA sites. Post-treatment FES associated with methylation in 6760 CpG sites. Majority of the DNA methylation changes were treatment effect in the overall CpG sites, the FES associated CpG sites, and risperidone associated CpG sites, except for the post-treatment FES associated CpG sites. There were 590 DNA methylation cites normalized by risperidone treatment. The methylation changes of these 590 CpG sites were related to alterations in symptom severity, spontaneous neurophysiological activity, and cognitive function. To our knowledge, this is the first longitudinal methylation study of drug treatment effect and side effect in psychiatric disorders to include parallel studies of neuroimaging and cognitive phenotypes. We identified FES-associated CpG sites not confounded by drug treatment as potential SCZ biomarkers. The normalization effect of risperidone monotherapy suggests that DNA methylation changes may serve as a predictive biomarker for treatment effect. The constructed methylation-phenotype network revealed a relationship between methylation and a wide range of biological and psychological variables.
Keywords: Biomarker, DNA methylation, risperidone treatment, first-episode schizophrenia

**Introduction**

For the majority of patients with schizophrenia (SCZ), treatment features second-generation antipsychotic drugs such as risperidone supported by psychosocial therapy. Risperidone has receptor affinities targeting dopamine, serotonin and other neurotransmitters.[1] Risperidone effectively treats acute psychosis and works to prevent SCZ relapse.[2] Although antipsychotic drugs bind to target receptors within hours of administration, clinical efficacy can take weeks, perhaps due to slower acting complex biological changes.[3] Accumulating evidence indicates that gene expression regulation, such as DNA methylation, may spark the clinical effect of antipsychotic drugs, [4-6] The epigenome-wide association studies of SCZ disease risk to date, a mix of disease-discordant monozygotic twins or case-control comparisons, [7-17] produced inconsistent results regarding changes in DNA methylation.[8] These inconsistencies may result from wide variance in illness duration and drug treatment histories of the patients studied.

Previous studies have shown antipsychotics influencing DNA methylation,[18-26] with olanzapine changing DNA methylation in the brains of mice[20], and clozapine changing DNA methylation in human peripheral leukocytes.[27] Again, studies to date involved primarily chronically treated patients with long histories of disease symptoms and varied drug treatments. Under these circumstances disease severity may muddle a clear measure of treatment effect. Alternatively, studying drug-naïve patients with only a first episode of SCZ (FES) would avoid these likely confounders and produce a clearer indication of the effects of antipsychotics on DNA methylation.

We have two aims in the current study: 1) identifying disease-related methylation changes before treatment, and 2) investigating acute antipsychotic treatment effects on
DNA methylation. We hypothesize that disease-related methylation changes occur before treatment, and that acute antipsychotic treatment may affect DNA methylation. We used a longitudinal cohort design to study the effects of the risperidone monotherapy on DNA methylation in patients with FES (Fig.1). We followed the drug naïve patients over the treatment course, recording phenotypic changes and monitoring DNA methylation. We also integrated retrospectively collected data from demographic matched controls to help differentiate treatment effect from the side-effect of methylation changes. We then explored whether risperidone-induced methylation changes correlated to brain phenotypes, with features including symptom severity, cognitive function, and spontaneous brain activity.

Fig.1. Overall study design.

(A) 1. Thirty-eight patients with first-episode drug-naïve schizophrenia (FES) and 38 demographically-matched individuals (healthy controls) participated. 2. We conducted differential analysis among FESs vs Control, post-FESs vs FESs, and post-FESs vs Control. 3. Comparison of the differential results. 4. Parallel DNA methylation changes with phenotypes changes. (B) Overall comparison of effect size between two differential analysis: pre-treatment FEP association analysis (pre-FEP vs control) and treatment association analysis (Post-FEP vs Pre-FEP)
Results and Discussion

1. FESs associated methylation enriched in neuronal function-related pathway

After quality control, 164,684 probes were left for further analysis. We found 4,885 CpG sites were differentially methylated between pretreatment FESs and controls (t-test, p < 0.05) as shown in Manhattan plot (Fig.2.A), none of them got the genome-wide significant with p < 1e-6. Most of CpG sites (3,782 out of 4,885, 77.42%) showed hypomethylation in the FESs. We found some top signals with several CpG sites located in one gene, such as the cg12407791 (p=2.03E-05) and cg07010633 (p=1.22E-04) at UNC13D (Table 2). The FESs associated CpG sites were enriched in neurogenesis (FDR <1.68e⁻¹²), generation of neurons (FDR <1.68e⁻¹²), and central nervous system development (FDR =4.04e⁻¹⁰) (Table 3). Using the replicate dataset, the 637 CpG sites out of the 4,885 were detected, and 6 CpG sites were replicated. They are cg08063724 at the first exon of MYCL1, cg17366294 at promoter of C4orf37, cg05119831 at gene body of PRPRN2, cg00933411 at the promoter of DLC1, cg17145652 at 5’UTR of RNF170 and cg24765079 at body of CDH1. We also evaluated the consistency of our findings with previously published SCZ-associated methylation results. Eleven CpG sites found by the largest EWAS in SCZ[7] were replicated in our dataset.

We also examined whether the differentially methylated CpG sites are enriched in the 108 loci by GWAS.[28] Among the 108 GWAS loci, there were 64 loci contained 770 CpG sites. In these 770 CpG sites, 77 of them were differentially methylated sites. Enrichment test showed that the GWAS loci had significant enrichment of the differentially methylated CpG sites (Fisher’s Exact test p <1.68e⁻¹²). Among the 4,885 differentially methylated CpG sites, 306 CpG sites showed highly correlated methylation between blood and brain using the Blood Brain DNA Methylation Comparison Tool.[29]
For the region level analysis, we generated 3,419 regions of gene body and 8,229 regions of promoter from the 164,684 CpG sites tested after quality control. We did not detect pre-treatment FES associated DMRs with P.adj < 0.05, but identified 341 gene body DMRs and 858 promoter DMRs with nominal p < 0.05.

2. Risperidone associated CpG sites and DMRs enriched in calcium signaling pathway.

We found one CpG site, cg08778598 at gene body of SDHAP3 genes, was significantly differential methylated between pre-treatment samples and post-treatment samples (P= 4.84e-7) (Fig. 2.B). Risperidone treatment increased 3% methylation of this CpG site. There were 5,979 CpG sites with nominal p < 0.05 in comparisons of pre-treatment versus post-treatment data, 3,486 (58.61% out of the 5,979 CpG sites) of these CpG sites increased their methylation level after treatment while 2,493 CpG sites decreased the methylation level after treatment. Using replicate data, 517 CpG sites of the 6,142 were detected, and 11 CpG sites were replicated. They are cg09991975 at the promoter of JOSDI, cg26309951 at 5’UTR of MORF4L2, cg21376883 at body ACTN2, cg01598046 at the promoter of TRAIP, cg00066816 at the promoter of IL12B, cg17617223 at the promoter of ZER1, cg15432938 at the promoter of FRAT1, cg15875120 at the promoter of FAM18A, cg22560190 at the promoter of CNTN1, cg12100791 at the promoter of PYCARD and cg15928446 at the promoter of PRR14.

Pathway analysis showed the 5,979 CpG sites enriched in brain related KEGG pathways such as axon guidance (FDR=1.60E-04), Wnt signaling pathway (FDR = 1.20E-03), MAPK signaling pathway (FDR=1.20E-03) and calcium signaling pathway (FDR=4.84E-03) (Table 3).

For the risperidone-induced differentially methylated regions, we did not detect any DMRs with P.adj < 0.05 in either gene body nor promoter regions, but we detected 210 DMRs in gene body and 555 DMRs in promoter regions with nominal p < 0.05.
These genes were functionally enriched for the calcium signaling pathway (FDR=0.0118) and long-term depression (FDR=0.0413). Of the above Entrez genes, the greatest changes were at sites CACANA1A, RYR1, NOS1, LTB4R2, and PTGER3.

3. Post-treatment FES-associated methylation

To help understand the treatment result on the patients, we compared the DNA methylation between post-treatment patients with FES and controls (Fig. 2.C). We found 6,760 CpG sites were differentially methylated with nominal $p < 0.05$. Similar to pre-treatment FES-associated DMPs, most CpG sites (4,034 out of 4,885, 70.00%) showed hypomethylation in post-treatment FES. Using replication data, we detected 3777 of the 6,760 CpG sites and replicated 8 CpG sites. Pathway analysis did not find any KEGG pathways enriched in the 6,760 CpG sites using FDR <0.05, but found several pathways with $p <0.05$, for example, endocrine resistance ($p=1.53e-3$), glycosylphosphatidylinositol (GPI)-anchor biosynthesis ($p=2.12e-3$), insulin signaling pathway ($p=4.13e-3$), alanine, aspartate and glutamate metabolism ($p=2.41e-2$), and thyroid hormone signaling pathway($p=2.92e-2$).

For the region level analysis, we detected 25 post-treatment FES-associated DMRs in the gene-body with a $P_{adj} < 0.05$, including TP73, PLEKHH3, CNTNAP1, MAD1L1, CHD5, RASA3, GRIN1, WSA5B2, FBXL18, AATK, ZFYVE21, NEURL1B, TRAPPC9, SEMA4C, TBCD, CUX1, LPHN1, CHD3, PRDM16, OBSCN, PLEC1, GALNT9, and PTPRN2. We found 451 DMRs in gene-body regions and 809 DMRs in promoter regions with nominal $p < 0.05$. 
Figure 2. Differential methylation.

Manhattan plot and QQ plot of the differentially methylated CpG sites between FES and controls in (A), Pre- and Post-treatment in (B), and post-treatment and control in (C).

4. Risperidone-induced treatment and side effect in methylation

By comparing the direction of effect size between two differential analysis: pre-treatment FEP association analysis (pre-FEP vs control) and treatment association analysis (Post-FEP vs Pre-FEP), we found that 63.02% of the 164,684 CpG sites showed treatment effect with contrasting up-/down-regulation in the two analysis, whereas 36.98% CpG sites showed side effect with common up-/down-regulation in the two analysis (Fig.1.B). For the 4,885 FES-associated CpG sites, 85.32% showed treatment effect, while only 14.68% showed side effect (Fig.3.A). Similar with FES-associated CpG sites, we found the 87.54% out of the Risperidone associated CpG sites showed treatment effect, while only 12.46% showed side effect (Fig.3.B). Different with FES-associated CpG sites and FES-associated CpG sites with majority
are treatment effect. Among the 5,979 post-treatment FES associated CpG sites, only 16.84% showed treatment effect, whereas 83.16% showed side effect (Fig.3.C).

![Figure 3. Treatment effect and side-effect](image)

The degree of treatment effect and side effect evident in the CpG sites for FEP-associated CpG sites (A), Risperidone-associated CpG sites (B), and post-treatment FEP associated CpG sites (C).

**5. Methylation-phenotype network**

We further calculated the overlap between the pre-treatment FES associated CpG sites and risperidone associated CpG sites, finding 590 overlapped CpG sites. From these overlapped sites, we also compared post-treatment FES to the healthy controls, identifying 580 normalized CpG sites. These 590 CpG sites mapped to 568 unique genes which contained 113 SCZ related candidate genes obtained from SZDB (http://www.szdb.org/) and NPdenovo (http://www.wzgenomics.cn/NPdenovo/), such as MAN2A1 (Supplementary Table S2).

To explore whether these normalized CpG sites can reflect the phenotypic changes in the brain, we correlated methylation changes to the phenotypic changes. They ranged from symptom severity, to cognitive function, to brain structures. We then found 284 out of the 580 normalized CpG sites that correlated with at least one phenotype (absolute correlation coefficient > 0.3, p <0.05, Supplementary Figure S1). These included two CpG sites (cg09175724 and cg19248041) correlated with five
phenotypic variables, nine CpG sites correlated with four phenotypic variables, 25 CpG sites correlated with three phenotypic variables, and 61 CpG sites correlated with two phenotypic variables. For example, cg09175724 at the 5'UTR of CDC42EP2, correlated with reducing rate of PANSS-Total score (correlation coefficient =0.40, p= 1.30E-02), changes of PANSS-Positive symptom score (correlation coefficient =0.57, p= 2.07E-04), changes of PANSS-General symptom score (correlation coefficient =0.36, p= 2.50E-02), and reducing rate of fALFF (resting state fMRI) in both left and right putamen (correlation coefficient =-0.39, p= 1.30E-02).

For the phenotypic variables, we found methylation changes after treatment in 96 sites correlating with changes in PANSS scores (Figure S2); in 129 sites, methylation changes correlated with reduced cognitive function; and in 122 sites, methylation changes were correlated with changes in spontaneous brain activity found in fMRI (Supplementary Figure S3) (absolute Spearman correlation coefficient > 0.3, p < 0.05).

Methylation of one CpG site (cg25535999) at the gene body of NR3C1, which encodes the glucocorticoid receptor, was normalized by treatment, and changes in that methylation correlated with PANSS-G, PANSS-T changes and cognitive improvement measured by the SCWT. Another CpG site, cg25114611 at the promoter of FKBP5 (TSS1500) was also normalized after treatment. Methylation changes of cg25114611 correlated with changes of nodal degree of anterior cingulate and paracingulate gyri (ACG, left and right) as well as with changes of nodal efficiency of right ACG. We found 11 normalized CpG sites in calcium pathway genes correlated with multiple phenotypic changes. For example, cg06204009 at the promoter of ATP2B3 and cg17119907 at the 5'UTR of NOS1 were normalized after treatment and correlated with the PANSS-G changes. In the calcium pathway, CpG site cg26571093 at the gene body of CACNA1H was normalized and correlated with changes in resting state brain function within the caudate nucleus (left and right) and with cognitive function.
improvement measured by the SCWT (Supplementary Table S3).

**Discussion and conclusion**

This is the first study of treatment-naïve patients with FES now receiving monotherapy with risperidone to examine methylation changes in peripheral blood to reflect treatment and side effect. This is also the first study to examine such changes as they relate to neuroimaging and cognitive phenotypes within this population. Through comprehensive comparisons between pre- and post-treatment FES populations and controls samples, we found treatment effect and side effect at the molecular level and identified hundreds of normalized CpG sites that parallel brain phenotypic changes.

Limiting our study to the FES population avoided the potentially confounding effects of chronic illness and drug treatment. This is important for both of our aims: 1) identifying disease-related methylation changes before treatment, and 2) investigating acute antipsychotic treatment effects on DNA methylation. Although our sample size is small due to the limited population, our findings in regard to these two aims are well supported by published research. The over-representation of FES-associated CpG sites within the SCZ-related GWAS loci is consistent with the largest SCZ EWAS study[7]. In regard to the treatment effect on DNA methylation, some of the associated genes are pivotal to neuronal function (e.g., *HDAC6*), while some have been previously associated with SCZ by GWASs (e.g., *MAN2A1, CNTN4, MEF2C*), and others are involved in *de novo* mutations related to SCZ (e.g., *NCKAP1, CAPRIN1, DNMT3A*). Several of the genes are also implicated in long-term synaptic depression and disease-associated calcium signaling pathways. Several evidences have implicated dysfunctional of these pathways in the pathophysiology of SCZ[30].

Notably, the use of monotherapy, consistent drug exposure period, and consistent dosage enhanced the validity of the pre- and post-treatment comparisons. Furthermore, having healthy controls as a reference allowed us to distinguish treatment effect from
side effects by equating changes in DNA methylation with common up/down regulation. We found majority of the risperidone induced DNA methylation changes had treatment effect. This result supports the clinical studies that antipsychotic drugs do more good than harm[31] for the patients in a molecular aspect. The comparison between the pre-treatment FES associated CpG sites and the post-treatment associated CpG sites showed us different effect pattern with majority of treatment effect in the pre-treatment FES and majority of side effect in the post-treatment FES. It means that the differences between the treated patients versus controls are more likely the drug induced difference instead of the disease induced methylation changes. These findings suggested that when we try to identify the new drug target using the drug naïve patients instead of the treated patients is critical to find the real signals.

For the first time in schizophrenia research, we linked post-antipsychotic methylation changes with changes in psychiatric symptoms as well as neuropsychological and neurophysiological abnormalities in patients with schizophrenia. We relate the methylation-phenotype network identified in this study to brain changes for two reasons. First, methylation status and methylation changes induced by the drug in blood cells correlate closely with methylation in the brain.[16, 32]. Second, while previous studies in schizophrenia associated methylation with changes in cognitive effect and MRI[33], we linked post-antipsychotic methylation changes with changes in psychiatric symptoms. The overlap of DNA methylation and established schizophrenia risk loci is of significant clinical relevance. Studies of methylation in blood cells may provide an important approach for understanding SCZ pathophysiology and drug treatment effectiveness.

Certain limitations of our clinical study are worth noting. Although our conclusions are supported statistically and were to a degree validated in an independent dataset, the results need to be validated in a larger cohort with FES. Future studies could identify the time course of methylation changes after therapy with several important clinical implications. Rapid onset of methylation may be a useful index of future
treatment response and therefore guide earlier changes in drug therapy for treatment non-responders. Variability in timing or extent of methylation changes across patients might account for variability in the speed and extent of treatment effect. Methylation changes that diminish or persist after longer term treatment might be related to course of illness, risk for relapse, etc. Last but not least, we measured the treatment and side effect in the peripheral blood which may not directly reflect the effect in the brain. Cause the brain tissue is impossible to get for these longitudinal studies, further animal model and cell lines studies are need.

**Materials and Methods**

**Participants**

Participants included 38 right-handed Chinese Han patients with FES (25 men; 13 women; mean age, 25.0 years; age range, 18-37) and 38 demographically-matched healthy controls (25 men; 13 women; mean age, 24.8 years; age range 18-32) (Table 1). Two attending psychiatrists diagnosed participants using the Structured Clinical Interview for DSM-IV-TR, patient version (SCID-I/P). All patients with FES had an onset of psychotic symptoms less than one-year before study participation. Healthy controls, had no history of Axis I or II disorders (Structured Clinical Interview for DSM-IV Axis I Disorders—Non-Patient Edition (SCID-I/NP); Structured Clinical Interview for DSM-IV Axis II Disorders), nor any known first-degree family history of psychiatric illness. Individuals with neurological disease, systemic disease or substance abuse disorders (such as Alcohol use disorders[34]) were excluded from this study.

All procedures were approved by the ethics committee of the Second Xiangya Hospital and the Second Affiliated Hospital of Xinxiang Medical University. All participants provided written informed consent and could discontinue study participation at any time.
Medication, psychiatric assessments and neuroimaging phenotyping

The SCZ cohort was treated with risperidone monotherapy at a dosage of 4mg to 6 mg/day for eight weeks, without the addition of mood stabilizers or antidepressants. Symptom severity was evaluated at baseline and follow-up with the Positive and Negative Syndrome Scale (PANSS)[35] scored to generate total score (PANSS-T), positive symptom score (PANSS-P), negative symptom score (PANSS-N) and the PANSS general psychopathological symptom score (PANSS-G). Three of them, PANSS-T, PANSS-P and PANSS-G, significantly improved with treatment (paired t test p < 0.001).

Magnetic resonance imaging (MRI) scans were performed on all participants using a 3T MRI scanner (Siemens Healthcare; Erlangen, Germany) with a 16-channel head coil. Diffusion tensor imaging, T1-weighted imaging and resting-state fMRI data were collected at baseline and again after 8 weeks. Spontaneous brain activity was quantified using the fractional amplitude of low-frequency fluctuations (fALFF) and regional homogeneity (ReHo). Detailed scanning parameters and analysis method for these MRI data were performed as previously described.[36, 37] Cognitive function was evaluated in parallel with MRI scanning using standardized and widely-used neuropsychological tests: Stroop Color Word Test (SCWT), Wisconsin Card Sorting Test (WCST), Trail Making Test (TMT), Verbal Fluency Test (VFT), and Digit Span Distraction Test (DSDT).[38-40]

All phenotypic variables (MRI, Cognition) used in this analysis were from brain regions or cognitive measures that changed significantly between pre- and post-treatment in the SCZ cohort or were significantly different between cohorts (supplementary Table S1A-S1C). Significantly improved phenotypes (paired t test p < 0.001) were included in the analyses to determine the relation between methylation changes and phenotypic improvement; changes observed after treatment were
generally consistent with earlier literature.[41-47] For spontaneous brain activity, we included fALFF in bilateral putamen and the right caudate and ReHo in the right caudate and left putamen. For cognitive function, we included changes of SCWT, WSCT, and TMT. Statistical analysis examining these phenotypic changes in relation to methylation changes are shown in supplementary Table S1A, S1B, and S1C.

**Quantification and analysis of DNA methylation**

**Microarray processing**

We collected blood samples from 38 healthy controls at baseline and 38 patients at two time-points (i.e., before and after risperidone treatment). Whole genome methylation status was then examined in 114 samples. DNA (500ng) was isolated using QIAamp DNA Blood Mini Kit (Qiagen; Germantown, MD) and treated with sodium bisulfite using the EZ DNA methylation kit (Zymo Research; Irvine, CA). DNA methylation was quantified using Infinium® Human Methylation 450K BeadChip (Illumina Inc.; San Diego, CA).

**Data processing**

All analyses were performed in R version 3.3.1. Raw intensity files were preprocessed and quantiles were normalized using the Bioconductor package ChAMP, version 2.0.1.[48] Proportions of methylation values (Illumina “Beta” scale) were calculated. After which, BMIQ[49] were used to adjust for type II bias. Probes were removed according to the following criteria: 1) detection \(p\)-value above 0.01 in one or more samples; 2) bead counts less than 3 in at least 5% of samples; 3) having SNPs; 4) aligning to multiple locations; and 5) identified in Nordlund et al.[50]; and 6) located in sex chromosomes. There were 164,684 probes remaining for differential methylation analysis. Batch and positional effect of each chip was adjusted using the ComBat empirical Bayesian approach [51]. The reference-based method was used to calculate cell type proportions[52]. We used linear regression to regress out effects of
cell type proportion, age, sex, smoking status, and drinking status for each probe.

**Power analysis**

Given a sample size of 76 for the risperidone-association analysis, there was 80% power to detect 12% mean methylation changes at $P < 1e^{-6}$. For the case control analysis of 76 samples, there was 80% power to detect 13% mean methylation changes at $P < 1e^{-6}$. The power analysis was based on the power simulations across a range of sample sizes and effect sizes according to the calculation of Saffari et al.[53].

**Identification of differentially methylated individual CpG sites and genomic regions**

To identify differentially methylated individual CpG sites, we conducted three epigenome-wide association analysis: the FES association analysis on pre-treatment FES verse controls, the risperidone association analysis on pre-treatment FES verse post-treatment FES, and the post-treatment FES association analysis on post-treatment FES verse control (Fig.1). Linear regression model in *Limma* package[54] was used for testing the differential DNA methylation between pre-/post-treatment FES and controls at each CpG site. Paired $t$-tests were used to test for differential DNA methylation between pre- and post-treatment samples in the patients. For multiple testing correction, we followed the Bonferroni correction and used the threshold of $1e^{-6}$ as recommended by Saffari et al. [53] and Rakyan et al.[8]. We reported the results with nominal ($p=0.05$) and genome-wide ($p=1e^{-6}$) significance levels.

To identify differentially methylated regions (DMRs), we used the mCSEA (Methylated CpGs Set Enrichment Analysis)[55] in R (version 3.5). We ran the mCSEA analysis for pre-treatment FES versus post-treatment FES (paired test), pre-treatment FES versus control samples, and post-treatment FES versus control samples. We ranked all evaluated CpG sites after quality control with the differential
statistics above. Then we used the \textit{mCSEATest} function to search promoter and gene body DMRs. We specified five CpGs as the minimum amount per region and performed 10000 permutations to calculate P value as the default. The p value was then adjusted by the Benjamini and Hochberg procedure for multiple testing correction.

**Estimation of risperidone-induced treatment and side effect in DNA methylation**

To estimate treatment and side effect induced by risperidone in DNA methylation, we compared the direction of effect size between two differential analysis: pre-treatment FEP association analysis (pre-FEP vs control) and treatment association analysis (Post-FEP vs Pre-FEP) (Fig. 1.B). In pre-treatment FEP association analysis, we defined up-regulated CpG sites as CpG sites that have higher methylation levels in patients than in controls, while the down-regulated CpG sites we defined as lower methylation levels in patients than in controls. In the treatment association analysis, the up-regulated CpG sites were defined as CpG sites with higher methylation levels in post-treatment patients than pre-treatment patients, while the down-regulated CpG sites had lower methylation levels in post-treatment patients than in pre-treatment patients.

Based on the two comparisons we divided the CpG sites into two groups: the CpG sites with common up/down regulation, and CpG sites with contrasting up/down regulation. Any changes in methylation in the contrasting CpG sites represent treatment effect. For example, before treatment a CpG site is down regulated in patients but not in controls; whereas after treatment, the methylation levels rise making them closer to normal. In the same way, the changes in CpG sites with common up/down regulation represent side effect, meaning that with side-effect the treatment makes the methylation levels in the patients even farther from the normal control.
To characterize the degree of treatment effect and side effect evident in the CpG sites, we estimated the percentages of CpG sites with common up/down regulation and contrasting up/down regulation for each of the following categories:

1. Total CpG sites after quality control, representing the overall effect of treatment on DNA methylation
2. FEP-associated CpG sites—dysfunctional CpG sites or genes
3. Risperidone-associated CpG sites

**Over-representation analysis**

To evaluate the enrichment of differential DNA methylation in SCZ GWAS signals, we downloaded the 108 loci from PGC website[28]. For every GWAS region, we counted the number of probes detected in this study and the number of the FES associated differentially methylated probes. SCZ related candidate genes were also obtained from SZDB (http://www.szdb.org/[56] and NPdenovo (http://www.wzgenomics.cn/NPdenovo/[57]). To evaluate the enrichment of differential DNA methylation with CpG sites that have brain-blood correlated methylation, we downloaded the CpG sites list from Blood Brain DNA Methylation Comparison Tool (http://epigenetics.essex.ac.uk/bloodbrain/). A two-sided Fisher’s exact test was used to estimate the enrichment. Gene ontology and KEGG pathway analyses were performed using missMethyl package, which consider the number of CpG islands corresponding to each gene[58].

**Replication**

We obtained a replication data set involving participants from a prior study involving similar entry criteria (untreated first episode schizophrenia), treatment (4-6 weeks risperidone), and phenotyping[59]. This sample included four controls (2 men, 2 women; 2 African American, 1 Hispanic and 1 White; age range, 27-30) and three
FESs (1 men, 2 women; 2 African American, 1 Hispanic; age range, 18-40) (Supplementary Table S1D). For each subject, blood samples were isolated twice pre- and post-treatment (six weeks). DNA methylation was quantified using Infinium Human Methylation 27 BeadChip (Illumina, CA) at the Northwestern University Core facility.

**Construction of the methylation-phenotype network**

To estimate parallel DNA methylation changes and phenotype, we constructed a methylation-phenotype network by correlating the changes of DNA methylation and phenotypic variables. We choose the CpG sites with normalized effect to construct the network analysis. The normalized CpG sites were those overlapped between FES-associated CpG sites and treatment induced CpG sites, excluded the post-FESs associated CpG sites. All the phenotypic variables used were listed in the Supplementary Table S1 based on previous publications.[36, 37] The relationships between pairs of variables (for example, methylation change of a CpG site and change of PANSS scores) were examined using Spearman rank correlation tests. Associations with an absolute correlation coefficient larger than 0.3 and a $p$-value smaller than 0.05 were plotted in the network, and these variables were treated as edges in the graph (Figure 2). The graph was made using Cytoscape[60] v3.5.0 (http://cytoscape.org/) software. False discovery rate (FDR) was used to correct for multiple comparisons. Correlations with a FDR corrected $p < 0.05$ were considered significant.

**Acknowledgments**

This work was supported by grants from the National Natural Science Foundation of China (81871057 and 81371480 to J.T; 81271484 and 81471361 to X.C.; 31970572, 81401114 and 31571312 to C.C.) the National Key Plan for Scientific Research and Development of China (2016YFC1306000) (to C. C.) and NIH grant 1 U01 MH103340-01, 1R01ES024988 (to C. L.), MH083888 (to J.R.B.). Wuhan Science
and Technology Bureau grant (2017060201010169 to M. H.). Central South University Graduate Project grant (502221702 to Y.X.).

Dr Hu, Dr Zong and Ms Xia had full access to all the data. Ms Xia takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. J. Tang, Dr X. Chen, Dr Liu and Dr C. Chen supervised this work and contributed equally as principal investigators.

Study concept and design: Jinsong Tang, Xiaogang Chen, Chunyu Liu, Chao Chen

Acquisition data: Maolin Hu, Xiaofen Zong, Jinsong Tang, Jeffrey R Bishop, Zongchang Li, Ying He, Yanhui Liao.

Analysis and interpretation of data: Yan Xia, Chao Chen, John Sweeney, Chunyu Liu, Leah Rubin, Bingshan Li, Jinsong Tang, Yanhui Liao, Xiaogang Chen.

Drafting of the manuscript: Yan Xia.

Critical revision of the manuscript for important intellectual content: Yan Xia, John Sweeney, Jinsong Tang, Chunyu Liu, Chao Chen, Yanhui Liao, Yunpeng Wang, Gina Giase, Jeffrey Bishop, Liz Kunney.

Statistical analysis: Yan Xia, Chao Chen, Bingsha Li, Jinsong Tang

Obtained funding: Jinsong Tang, Xiaogang Chen, Chao Chen, Chunyu Liu, Maolin Hu, Yan Xia, Jeffrey Bishop.

Study supervision: Jinsong Tang, Xiaogang Chen, Chao Chen, Chunyu Liu.

Dr. Sweeney consulted to Takeda. None of the other authors report potential conflicts of interest.

Reference


3. Thomas EA: Molecular profiling of antipsychotic drug function: convergent


55. Martorell-Marugan J, Gonzalez-Rumayor V, Carmona-Saez P: mCSEA:


### Table 1. Demographic and Clinical Characteristics of Drug-Naïve First Episode Schizophrenia Patients and Matched Healthy Control Participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (SD)</th>
<th>Statistical Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FESP</td>
<td>Healthy Control</td>
</tr>
<tr>
<td>Age</td>
<td>25.00(4.95)</td>
<td>24.76(4.56)</td>
</tr>
<tr>
<td>Sex, No.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Female</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Education, years</td>
<td>10.48(2.84)</td>
<td>11.05(2.91)</td>
</tr>
<tr>
<td>Handedness(r/l)</td>
<td>38/0</td>
<td>38/0</td>
</tr>
<tr>
<td>Alcohol use(y/n)a</td>
<td>6/32</td>
<td>9/29</td>
</tr>
<tr>
<td>Tobacco use(y/n)</td>
<td>8/30</td>
<td>8/30</td>
</tr>
<tr>
<td>Family history(y/n)b</td>
<td>14/24</td>
<td>0/38</td>
</tr>
</tbody>
</table>

**Abbreviation:**
FESPs, first episode drug-naïve schizophrenia patients

*a* Alcohol use disorders identification test (AUDIT) was used to assess alcohol use.

*b* Family history provided by the patient and their family members. We followed their family tree back three generations on both their maternal and paternal branches. The medical history included assessment of schizophrenia spectrum and affective disorder illness.

### Table 2. Top signals for FESPs associated differential methylation and risperidone-induced methylation

<table>
<thead>
<tr>
<th>Probe information</th>
<th>Statistical Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probe</td>
<td>Chr</td>
</tr>
<tr>
<td>FESPs associated differential methylation</td>
<td></td>
</tr>
<tr>
<td>cg12407791</td>
<td>17</td>
</tr>
<tr>
<td>cg12070285</td>
<td>6</td>
</tr>
<tr>
<td>cg00401265</td>
<td>X</td>
</tr>
<tr>
<td>cg13918808</td>
<td>X</td>
</tr>
<tr>
<td>cg15150970</td>
<td>2</td>
</tr>
<tr>
<td>cg15226147</td>
<td>19</td>
</tr>
<tr>
<td>cg25289658</td>
<td>X</td>
</tr>
<tr>
<td>cg03598919</td>
<td>X</td>
</tr>
<tr>
<td>cg07010633</td>
<td>17</td>
</tr>
<tr>
<td>cg13728834</td>
<td>9</td>
</tr>
</tbody>
</table>

*CGs which were not certified by peer review is the author/funder. All rights reserved. No reuse allowed without permission.*
### Risperidone-induced methylation changes

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Chromosome</th>
<th>Position</th>
<th>Gene Symbol</th>
<th>Annotation</th>
<th>Body</th>
<th>Promoter</th>
<th>t</th>
<th>tcorr</th>
</tr>
</thead>
<tbody>
<tr>
<td>cg08778598</td>
<td>X</td>
<td>5</td>
<td>SDHAP3</td>
<td>Body</td>
<td>-6.084</td>
<td>4.84E-07</td>
<td>0.028</td>
<td></td>
</tr>
<tr>
<td>cg04174838</td>
<td>X</td>
<td>3</td>
<td>LOC389906</td>
<td>IGR</td>
<td>-5.265</td>
<td>6.21E-06</td>
<td>0.027</td>
<td></td>
</tr>
<tr>
<td>cg01445411</td>
<td>2</td>
<td>1358684</td>
<td>SNTG2</td>
<td>Body</td>
<td>-5.117</td>
<td>9.83E-06</td>
<td>0.013</td>
<td></td>
</tr>
<tr>
<td>cg25396787</td>
<td>X</td>
<td>3733991</td>
<td>LOC389906</td>
<td>IGR</td>
<td>-5.106</td>
<td>1.02E-05</td>
<td>0.031</td>
<td></td>
</tr>
<tr>
<td>cg10193721</td>
<td>14</td>
<td>24780691</td>
<td>LTBR4</td>
<td>Body</td>
<td>-5.029</td>
<td>1.29E-05</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>cg06721546</td>
<td>5</td>
<td>1594808</td>
<td>SDHAP3</td>
<td>Promoter</td>
<td>-5.003</td>
<td>1.40E-05</td>
<td>0.025</td>
<td></td>
</tr>
<tr>
<td>cg05571310</td>
<td>17</td>
<td>72350354</td>
<td>KIF19</td>
<td>Body</td>
<td>-4.995</td>
<td>1.43E-05</td>
<td>0.016</td>
<td></td>
</tr>
<tr>
<td>cg27149073</td>
<td>5</td>
<td>1594330</td>
<td>SDHAP3</td>
<td>Body</td>
<td>-4.988</td>
<td>1.46E-05</td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>cg23823908</td>
<td>1</td>
<td>71512485</td>
<td>PTGER3</td>
<td>1stExon</td>
<td>-4.861</td>
<td>2.17E-05</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>cg19761502</td>
<td>21</td>
<td>40759534</td>
<td>WRB</td>
<td>Body</td>
<td>-4.673</td>
<td>3.86E-05</td>
<td>0.018</td>
<td></td>
</tr>
<tr>
<td>cg11633514</td>
<td>7</td>
<td>100183910</td>
<td>LRCH4</td>
<td>Promoter</td>
<td>-4.634</td>
<td>4.35E-05</td>
<td>0.006</td>
<td></td>
</tr>
<tr>
<td>cg15949805</td>
<td>7</td>
<td>63505714</td>
<td>ZNF727</td>
<td>Promoter</td>
<td>-4.579</td>
<td>5.14E-05</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>cg08234507</td>
<td>11</td>
<td>64990959</td>
<td>SLC22A20</td>
<td>Body</td>
<td>4.554</td>
<td>5.55E-05</td>
<td>-0.010</td>
<td></td>
</tr>
<tr>
<td>cg17477052</td>
<td>10</td>
<td>71596731</td>
<td>COL13A1</td>
<td>Body</td>
<td>-4.525</td>
<td>6.06E-05</td>
<td>0.035</td>
<td></td>
</tr>
<tr>
<td>cg03066788</td>
<td>8</td>
<td>28175285</td>
<td>PNOC</td>
<td>UTR</td>
<td>-4.501</td>
<td>6.50E-05</td>
<td>0.032</td>
<td></td>
</tr>
<tr>
<td>cg14771419</td>
<td>7</td>
<td>142012988</td>
<td>PRSS58</td>
<td>IGR</td>
<td>-4.500</td>
<td>6.54E-05</td>
<td>0.028</td>
<td></td>
</tr>
<tr>
<td>cg01047586</td>
<td>2</td>
<td>176933407</td>
<td>EVX2</td>
<td>IGR</td>
<td>-4.471</td>
<td>7.13E-05</td>
<td>0.020</td>
<td></td>
</tr>
<tr>
<td>cg23958373</td>
<td>8</td>
<td>599963</td>
<td>ERICH1</td>
<td>IGR</td>
<td>4.414</td>
<td>8.48E-05</td>
<td>-0.025</td>
<td></td>
</tr>
<tr>
<td>cg22248011</td>
<td>6</td>
<td>52442381</td>
<td>TRAM2</td>
<td>Promoter</td>
<td>-4.414</td>
<td>8.48E-05</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>cg07234876</td>
<td>8</td>
<td>600039</td>
<td>ERICH1</td>
<td>IGR</td>
<td>4.409</td>
<td>8.59E-05</td>
<td>0.031</td>
<td></td>
</tr>
<tr>
<td>cg10616337</td>
<td>20</td>
<td>5988410</td>
<td>CRLS1</td>
<td>Promoter</td>
<td>4.405</td>
<td>8.70E-05</td>
<td>0.012</td>
<td></td>
</tr>
<tr>
<td>cg18306861</td>
<td>14</td>
<td>67879101</td>
<td>PLEK2</td>
<td>Promoter</td>
<td>-4.389</td>
<td>9.13E-05</td>
<td>0.017</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** Chr, chromosome; FESPs, first episode drug naïve schizophrenia patients

*a* Gene name with Illumina gene annotation

*b* Indicates if the loci overlap with untranslated region (UTR), first Exon (1stExon), gene body, intergenic region (IGR) or promoter (upstream of transcription start site,)

*c* For FESPs associated differential methylation, it is t value, for risperidone-induced differential methylation, it is paired t value.

*d* The mean difference between patients and controls, for FESPs associated differential methylation, is the mean methylation value of FESPs minus CTLs. For risperidone-induced methylation change, it is the mean methylation value of post-treatment minus pre-treatment

### Table 3. Functional annotation for FESPs associated differential methylation, Risperidone-induced differential methylation and normalized methylation genes

<table>
<thead>
<tr>
<th>Gene set</th>
<th>Description</th>
<th>C*</th>
<th>O*</th>
<th>P Value</th>
<th>FDR corrected P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FESPs associated differential methylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GO</td>
<td>neurogenesis</td>
<td>1414</td>
<td>216</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
</tr>
<tr>
<td>GO:0048699</td>
<td>generation of neurons</td>
<td>1319</td>
<td>204</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
</tr>
<tr>
<td>GO:0030182</td>
<td>neuron differentiation</td>
<td>1197</td>
<td>188</td>
<td>3.33E-16</td>
<td>1.68E-12</td>
</tr>
<tr>
<td>GO:0007417</td>
<td>central nervous system development</td>
<td>890</td>
<td>144</td>
<td>1.33E-13</td>
<td>4.04E-10</td>
</tr>
<tr>
<td>GO:2000026</td>
<td>regulation of multicellular organismal development</td>
<td>1675</td>
<td>225</td>
<td>9.14E-12</td>
<td>2.30E-08</td>
</tr>
</tbody>
</table>

Risperidone-induced differential methylation

**KEGG**

| hsa04360 | Axon guidance | 177 | 66 | 5.30E-07 | 1.60E-04 |
| hsa04310 | Wnt signaling pathway | 143 | 53 | 8.51E-06 | 1.20E-03 |
| hsa04010 | MAPK signaling pathway | 255 | 83 | 1.19E-05 | 1.20E-03 |
| hsa04390 | Hippo signaling pathway | 154 | 54 | 4.32E-05 | 2.62E-03 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells | 142 | 50 | 7.27E-05 | 3.67E-03 |
| hsa04020 | Calcium signaling pathway | 182 | 60 | 1.28E-04 | 4.84E-03 |
| hsa04144 | Endocytosis | 260 | 77 | 7.24E-04 | 1.99E-02 |

**GO**

| GO:0007409 | axonogenesis | 417 | 160 | 0.00E+00 | 0.00E+00 |
|GO:0007417 | central nervous system development | 890 | 327 | 0.00E+00 | 0.00E+00 |
|GO:0007420 | brain development | 668 | 240 | 0.00E+00 | 0.00E+00 |
|GO:0009790 | embryo development | 945 | 328 | 0.00E+00 | 0.00E+00 |
|GO:0022008 | neurogenesis | 1414 | 490 | 0.00E+00 | 0.00E+00 |
|GO:0030182 | neuron differentiation | 1197 | 422 | 0.00E+00 | 0.00E+00 |
|GO:0030900 | forebrain development | 358 | 157 | 0.00E+00 | 0.00E+00 |

Normalized methylation genes

**GO**

| GO:0022008 | neurogenesis | 1414 | 123 | 1.84E-14 | 1.58E-10 |
|GO:0048699 | generation of neurons | 1319 | 116 | 5.62E-14 | 2.40E-10 |
|GO:0030182 | neuron differentiation | 1197 | 107 | 2.25E-13 | 4.81E-10 |
|GO:0048666 | neuron development | 951 | 86 | 3.87E-11 | 6.61E-08 |
|GO:0031175 | neuron projection development | 811 | 73 | 1.65E-09 | 2.10E-06 |
|GO:0048667 | cell morphogenesis involved in neuron differentiation | 506 | 51 | 1.50E-08 | 1.21E-05 |
|GO:0048812 | neuron projection morphogenesis | 552 | 54 | 1.56E-08 | 1.21E-05 |
|GO:0051960 | regulation of nervous system development | 760 | 65 | 9.54E-08 | 5.44E-05 |
|GO:0007417 | central nervous system development | 890 | 72 | 1.70E-07 | 8.55E-05 |
|GO:0007267 | cell-cell signaling | 1557 | 109 | 2.07E-07 | 9.83E-05 |

Abbreviations:

a) Total number of genes in the term.

b) Number of genes in the term with overlap in FESP associated differential methylation.

Risperidone-induced differential methylation and normalized gene methylation